01
Overview
PegBio is advancing PB-119, its main GLP-1 receptor agonist for diabetes which is nearing domestic approval in China. The company is planning a Hong Kong IPO to transition to an operating profit.
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Synthetic peptidesSmall molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on PegBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PegBio.